Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Vitamin D deficiency and low ionized calcium are linked with semen quality and sex steroid levels in infertile men

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Age-related changes in human Leydig cell status

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Polycystic ovary syndrome and offspring risk of congenital heart defects: a nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. WNT signalling in the normal human adult testis and in male germ cell neoplasms

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Fetal fraction of cell-free DNA in pregnancies after fresh or frozen embryo transfer following assisted reproductive technologies

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. DIAGNOSIS OF ENDOCRINE DISEASE: Sex steroid action in adolescence: too much, too little; too early, too late

    Research output: Contribution to journalReviewResearchpeer-review

  2. Age-related changes in human Leydig cell status

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cyclosporine and COVID-19: Risk or favorable?

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

STUDY QUESTION: Are low vitamin D levels linked with semen quality and sex steroids in infertile men?

SUMMARY ANSWER: Infertile men with vitamin D deficiency had lower sperm motility, total numbers of motile sperm, Inhibin B, sex-hormone-binding-globulin (SHBG) and testosterone/estradiol ratio, but higher levels of free sex steroids, than infertile men with normal vitamin D levels.

WHAT IS KNOWN ALREADY: Low vitamin D levels have been associated with decreased sperm motility in healthy men, but a relationship between vitamin D and calcium with semen quality and especially sex steroids has not been sufficiently described in infertile men.

STUDY DESIGN, SIZE, DURATION: This study comprises baseline characteristics of 1427 infertile men screened from 2011 to 2014 for inclusion in a randomized clinical trial, the Copenhagen-Bone-Gonadal Study.

PARTICIPANTS/MATERIALS, SETTING, METHODS: In total 1427 infertile men, consecutively referred to our tertiary andrological centre for fertility workup, underwent a physical examination and had semen quality assessed based on two samples and blood analysed for serum testosterone, SHBG, estradiol, inhibin B, luteinizing hormone, follicle-stimulating hormone (FSH), 25-hydroxyvitamin D (25-OHD), ionized calcium (Ca(2+)) and karyotype. There were 179 men excluded due to serious comorbidities or anabolic steroid usage, leaving 1248 patients for analyses.

MAIN RESULTS AND THE ROLE OF CHANCE: Men with 25-OHD >75 nmol/l had higher sperm motility and 66 and 111% higher total numbers of motile spermatozoa after 45 and 262 min, respectively, than men with 25-OHD <25 nmol/l (all P < 0.05). SHBG levels and testosterone/estradiol ratios were 15 and 14% lower, respectively, while free testosterone and estradiol ratios were 6 and 13% higher, respectively, in men with 25-OHD <25 nmol/l (all P < 0.05). Men with lower Ca(2+) levels had higher progressive sperm motility and inhibin B/FSH ratio but lower testosterone/estradiol ratio (all P < 0.05).

LIMITATIONS, REASONS FOR CAUTION: All outcomes presented are predefined end-points but inferral of causality is compromised by the descriptive study design. It remains to be shown whether the links between vitamin D, calcium, semen quality and sex steroids in infertile men are causal.

WIDER IMPLICATIONS OF THE FINDINGS: The associations between vitamin D deficiency and low calcium with semen quality and sex steroids support the existence of a cross-link between regulators of calcium homeostasis and gonadal function in infertile men.

STUDY FUNDING/COMPETING INTERESTS: This study was supported by the Danish Agency for Science, Technology and Innovation, Hørslev Fonden, Danish Cancer Society and Novo Nordisk Foundation. There are no conflicts of interest.

TRIAL REGISTRATION NUMBER: NCT01304927.

DATE OF TRIAL REGISTRATION: 25 February 2011.

DATE OF ENROLMENT OF FIRST PATIENT: 8 March 2011.

Original languageEnglish
JournalHuman reproduction (Oxford, England)
Volume31
Issue number8
Pages (from-to)1875-85
Number of pages11
ISSN0268-1161
DOIs
Publication statusPublished - Aug 2016

    Research areas

  • Journal Article

ID: 49276979